



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/8483/2012

European Medicines Agency decision P/0060/2012

of 26 March 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-von Willebrand Factor Nanobody (ALX-0081) (EMA-001157-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0060/2012

of 26 March 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for anti-von Willebrand Factor Nanobody (ALX-0081) (EMA-001157-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Ablynx NV on 10 May 2011 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 February 2012, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation, and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for anti-von Willebrand Factor Nanobody (ALX-0081), powder and solvent for solution for injection, subcutaneous use, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for anti-von Willebrand Factor Nanobody (ALX-0081), powder and solvent for solution for injection, subcutaneous use, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for anti-von Willebrand Factor Nanobody (ALX-0081), powder and solvent for solution for injection, subcutaneous use, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Ablynx NV, Technologiepark 21, 9052 – Zwijnaarde, Belgium.

Done at London, 26 March 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/8483/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001157-PIP01-11

Scope of the application

Active substance(s):

Anti-von Willebrand Factor Nanobody (ALX-0081)

Condition(s):

Treatment of thrombotic thrombocytopenic purpura

Pharmaceutical form(s):

Powder and solvent for solution for injection

Route(s) of administration:

Subcutaneous use

Intravenous use

Name/corporate name of the PIP applicant:

Ablynx NV

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Ablynx NV submitted for agreement to the European Medicines Agency on 10 May 2011 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 15 June 2011.

Supplementary information was provided by the applicant on 17 November 2011.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 10 February 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of Thrombotic Thrombocytopenic Purpura

The waiver applies to:

- Infants and children from birth to less than 2 years of age;
- for powder and solvent for solution for injection, subcutaneous and intravenous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of Thrombotic thrombocytopenic purpura

2.1.1. Indication(s) targeted by the PIP

Treatment of acquired thrombotic thrombocytopenic purpura.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection.

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	3	Study 1: Modelling/Simulation (M/S) study using a semi-mechanistic population PK/PD model with parallel linear clearance of the free ALX-0081 Nanobody and non-linear clearance of the Nanobody-vWF complex. Study 2: Single-blind, randomised, parallel design, placebo-controlled study to assess efficacy and safety of anti-von Willebrand factor nanobody as adjunctive treatment to plasma exchange in adults/adolescents with acquired thrombotic thrombocytopenic purpura (TTP). Study 3: Open-label study to assess efficacy of ALX-0081 for the treatment of acquired TTP as adjunctive therapy to plasma exchange (PE) in adults and paediatric patients.

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety and efficacy issues in relation to paediatric use:	No.
Date of completion of the paediatric investigation plan:	By March 2017.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes.